Source: Eur Respir J, 52 (6) 1801482; 10.1183/13993003.01482-2018



Rating:

Share or cite this content

Citations should be made in the following way:
Cécile Rotenberg, Valérie Besnard, Pierre-Yves Brillet, Stéphane Giraudier, Hilario Nunes, Dominique Valeyre. Dramatic response of refractory sarcoidosis under ruxolitinib in a patient with associated JAK2-mutated polycythemia. Eur Respir J, 52 (6) 1801482; 10.1183/13993003.01482-2018

Member's Comments

No comment yet.

Related content which might interest you: Rituximab in the treatment of refractory pulmonary sarcoidosis Source: Eur Respir J 2014; 43: 1525-1528 Year: 2014 Long-term response to prednisone in newly treated patients with pulmonary sarcoidosis Source: Virtual Congress 2021 – Better understanding of sarcoidosis: new keys Year: 2021 Severe asthma with blood hypereosinophilia associated with JAK2 V617F mutation: a case series Source: Eur Respir J, 53 (6) 1802248; 10.1183/13993003.02248-2018 Year: 2019 Fully reversible pulmonary arterial hypertension associated with dasatinib treatment for chronic myeloid leukaemia Source: Eur Respir J 2011; 37: 218-220 Year: 2011 Effect of ABPA treatment in severe asthma patients with acute and relapsed disease Source: Virtual Congress 2020 – Advances in asthma treatment Year: 2020 Granulomatous lung disease in lymphoma patient after rituximab treatment Source: Virtual Congress 2020 – Interstitial lung diseases Year: 2020 Follow-up of the patients with newly diagnosed sarcoidosis treated with oral corticosteroids. Features associated with chronic sarcoidosis Source: Annual Congress 2008 - Sarcoidosis and other interstitial lung diseases Year: 2008 Clinical features of patients with sarcoidosis associated with Sjogren‘s syndrome Source: Eur Respir J 2005; 26: Suppl. 49, 32s Year: 2005 Long-term treatment with infliximab in patients with sarcoidosis Source: Annual Congress 2011 - Different profiles of sarcoidosis and other granulomatous disorders Year: 2011 Pulmonary toxicity after long-term treatment with lenalidomide in two myeloma patients Source: Eur Respir Rev 2013; 22: 93-95 Year: 2013 Prediction of relapse after discontinuation of infliximab therapy in severe sarcoidosis Source: Eur Respir J 2014; 43: 602-609 Year: 2013 Effect of infliximab on lung function and well-being in patients with refractory sarcoidosis Source: Annual Congress 2011 - Different profiles of sarcoidosis and other granulomatous disorders Year: 2011 Osteopontin in severe refractory asthma Source: Annual Congress 2009 - Airways remodelling Year: 2009 Rituximab treatment of a case of anti-syntetase syndrome with severe interstitial lung disease and acute respiratory failure Source: Annual Congress 2010 - Clinical issues in diffuse parenchymal lung disease Year: 2010 Tuberculosis complicating imatinib treatment for chronic myeloid leukaemia Source: Eur Respir J 2009; 33: 670-672 Year: 2009 Non-infectious pulmonary involvement in myelodysplastic syndrome Source: Annual Congress 2008 - Miscellaneous aspects of interstitial lung disease Year: 2008 Improvement of the clinical response to infiximab in refractory sarcoidosis by reducing the dose interval Source: Eur Respir J 2007; 30: Suppl. 51, 245s Year: 2007 Rate of respiratory symptoms in naïve patients with Chronic lymphocytic leukemia Source: Virtual Congress 2020 – Rare lung diseases and lung manifestations of extrapulmonary diseases Year: 2020 High-doses glucocorticosteroid treatment in sarcoidosis patients Source: Eur Respir J 2007; 30: Suppl. 51, 118s Year: 2007 An autopsy case of pulmonary veno-occlusive disease refractory to imatinib Source: Eur Respir J 2011; 37: 968-970 Year: 2011